Data / Form D filings / STEM CELL THERAPEUTICS CORP
STEM CELL THERAPEUTICS CORP: Form D filing
STEM CELL THERAPEUTICS CORP, a biotechnology company in Toronto, Ontario, Canada, filed a Form D with the SEC in 2013. The latest, on December 23, 2013, reports $30.3 million sold of a $60.7 million offering to 22 investors.
Find out what STEM CELL THERAPEUTICS CORP does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 96 Skyway Avenue, Toronto, Ontario, Canada, M9W 4
- Phone
- (416) 457-4670
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Ontario, Canada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1392333
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 23, 2013 | New notice | $60,697,057 | $30,298,825 | $30,398,232 | 22 | Dec 13, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Robert Uger | Executive Officer | |
| Niclas Stiernholm | Executive Officer, Director | |
| Penka Petrova | Executive Officer | |
| James Todd Parsons | Executive Officer | |
| Ronald Dean Peterson | Director | |
| Michael G. Moore | Director | |
| Henry G. Friesen | Director | |
| James Michael DeMesa | Director | |
| David Geoffrey Peter Allan | Director | |
| Calvin Ralph Stiller | Director |
Every Form D from the week of Dec 23, 2013 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what STEM CELL THERAPEUTICS CORP reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.